Yolken R H, Hilgartner M W
Am J Dis Child. 1978 Mar;132(3):291-3. doi: 10.1001/archpedi.1978.02120280075016.
The development of factor VIII inhibitors has been a major problem in the management of hemophiliacs. The use of prothrombin complex concentrates (PCC) has been advocated as a method of overcoming this problem. We utilized PCC in the treatment of nine hemophiliac patients who had significant levels of inhibitor. Acute bleeding episodes were successfully treated in all nine patients. Single infusions of PCC were usually adequate for control of joint and soft tissue bleeding episodes, while multiple infusions were usually required for more serious hemorrhages. In addition, programs of repeated infusions were used to heal chronically inflamed joints in three patients. The only side effect of treatment was one episode of asymptomatic elevation of liver function values that resolved spontaneously. There were no thrombotic events associated with the PCC infusions. Therapy with PCC is recommended for the management of hemophiliacs with factor VIII inhibitors.
在血友病患者的治疗中，凝血因子 VIII 抑制剂的产生一直是一个主要问题。有人主张使用凝血酶原复合物浓缩剂（PCC）来解决这一问题。我们对 9 名有显著水平抑制剂的血友病患者使用了 PCC 进行治疗。所有 9 名患者的急性出血发作均得到成功治疗。单次输注 PCC 通常足以控制关节和软组织出血发作，而更严重的出血通常需要多次输注。此外，还采用重复输注方案来治愈 3 名患者的慢性炎症关节。治疗的唯一副作用是肝功能值有一次无症状升高，随后自行消退。没有与 PCC 输注相关的血栓形成事件。对于有凝血因子 VIII 抑制剂的血友病患者的管理，建议采用 PCC 治疗。
